Jacobs Levy Equity Management
RPRX

Jacobs Levy Equity Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-114,165
Closed -$137K – 1103
2017
Q1 		$137K Sell
114,165
-153,965
-57% -$192K ﹤0.01% 834
2016
Q4 		$354K Hold
268,130
– – 0.01% 735
2016
Q3 		$560K Sell
268,130
-46,900
-15% -$92.8K 0.01% 697
2016
Q2 		$507K Sell
315,030
-8,399
-3% -$16.1K 0.01% 753
2016
Q1 		$314K Buy
+323,429
New +$316K 0.01% 859

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jacobs Levy Equity Management's RPRX Position: Q2 2017 in Review

Jacobs Levy Equity Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2017, closing a stake of 114,165 shares — an estimated $137K sold.

Jacobs Levy Equity Management first reported a position in RPRX in Q1 2016 and held it in 5 quarters. The position peaked at $560K in Q3 2016. 29 funds tracked by Wall St. Rank hold RPRX as of Q2 2017.

  • Jacobs Levy Equity Management reported no remaining Repros Therapeutics Inc. position as of Q2 2017 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 114,165 Repros Therapeutics Inc. shares in Q2 2017, an estimated $137K.
  • Jacobs Levy Equity Management first reported a position in Repros Therapeutics Inc. in Q1 2016 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Repros Therapeutics Inc. position peaked at $560K in Q3 2016.
  • 29 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2017.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2017, filed 14 Aug 2017.